William Blair Weighs in on AbbVie’s Q2 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at William Blair cut their Q2 2025 earnings per share estimates for shares of AbbVie in a research report issued to clients and investors on Monday, July 14th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $2.88 per share for the quarter, down from their previous forecast of $3.27. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The firm had revenue of $13.34 billion during the quarter, compared to analysts’ expectations of $12.91 billion. During the same quarter in the previous year, the business posted $2.31 earnings per share. The business’s quarterly revenue was up 8.4% compared to the same quarter last year.

A number of other research analysts have also issued reports on ABBV. The Goldman Sachs Group reiterated a “neutral” rating and issued a $194.00 target price on shares of AbbVie in a report on Tuesday, April 8th. Guggenheim boosted their price objective on AbbVie from $214.00 to $216.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. BNP Paribas upgraded shares of AbbVie to a “hold” rating in a research note on Thursday, May 8th. Cantor Fitzgerald started coverage on shares of AbbVie in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $210.00 price target for the company. Finally, Evercore ISI boosted their price target on shares of AbbVie from $204.00 to $205.00 and gave the stock an “outperform” rating in a report on Monday, April 28th. Eight equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $211.29.

AbbVie Stock Performance

NYSE:ABBV opened at $190.53 on Wednesday. AbbVie has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a fifty day simple moving average of $186.95 and a two-hundred day simple moving average of $189.20. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The company has a market cap of $336.55 billion, a price-to-earnings ratio of 81.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.48.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be issued a $1.64 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.44%. AbbVie’s payout ratio is 279.15%.

Hedge Funds Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie in the second quarter valued at approximately $25,000. TD Capital Management LLC grew its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the last quarter. EnRich Financial Partners LLC raised its position in AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after buying an additional 110 shares during the last quarter. Abound Financial LLC purchased a new position in AbbVie during the 1st quarter worth $30,000. Finally, Prudent Man Investment Management Inc. acquired a new stake in shares of AbbVie in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.